<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High dose chemoradiotherapy and haematopoietic stem cell transplantation (SCT) is used as primary therapy for patients diagnosed with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-three adults presented with <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in British Columbia between 1987 and 2003 </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty patients had bone marrow involvement </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients did not proceed to SCT because of chemorefractory disease (n = 9) or other reasons (n = 7) </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-seven patients proceeded to SCT and had a 3-year event-free survival of 51% </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, approximately 50% of patients with chemosensitive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> who undergo SCT can be cured; however, a significant number of patients will not proceed to SCT because of early resistance or recurrence </plain></SENT>
</text></document>